Dr.
HOOKIPA's Board of Directors will now consist of 8 members, including Dr.
About HOOKIPA
HOOKIPA's proprietary arenavirus-based technologies, VaxWave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration to augment and refresh immune responses. TheraT has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches. HOOKIPA's 'off-the-shelf' viral vectors target dendritic cells in vivo to activate the immune system.
HOOKIPA's VaxWave-based prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial in CMV-negative patients awaiting kidney transplantation from living CMV-positive donors as well as CMV-positive patients awaiting kidney transplantation from CMV-positive or -negative donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with
In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The TheraT based lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in
Contact:
Tel: +44 (0)20 7457 2020
Email: hookipa@instinctif.com
(C) 2020 Electronic News Publishing, source